Kohei Shitara: Final OS analysis of KN585
Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, shared a post on X:
“Final OS analysis of KN585 published in Journal of Clinical Oncology. OS HR has been changed from 0.90 at primary The Lancet Oncology to 0.86. HR in FLOT cohort also shifted from 1.02 to 0.81. Hoping MATTERHORN OS HR will also further improve with longer follow-up. ”
Title: Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
Authors: Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz, Takashi Oshima, Nina Karaseva, Mikhail Osipov, Hisateru Yasui, Hiroshi Yabusaki, Sergey Afanasyev, Young-Kyu Park, Salah Eddin Al-Batran, Takaki Yoshikawa, Patricio Yanez, Filippo Pietrantonio, Sara Lonardi, Xiao Fang, Yanfen Guan, Adriana Valderrama, Pierre Leconte, Pooja Bhagia, Yung-Jue Bang
Read the Full Article.
More posts featuring Kohei Shitara.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023